MOTS-c Dosage, half-life & reference guide
Also known as Mitochondrial Open Reading Frame of the 12S rRNA-c
A peptide encoded by your mitochondrial DNA, the energy-producing organelles inside every cell. In mice it activates AMPK, the pathway exercise triggers, improving insulin sensitivity and exercise capacity, which is why it's called an "exercise mimetic".
- Studied range
- 5–10 mg
- How often
- 2–3× weekly
- Half-life
- Hours
- Evidence
- ●
●●Emerging - Routes
- SubQ, IM
Studied in research — not a recommendation.
How it works.
Mitochondria-derived peptide that regulates metabolic homeostasis. In mouse and cell studies it activates the AMPK pathway, improves insulin sensitivity and exercise capacity, and slows some signs of aging.
Commonly reported: More energy and better workout endurance over the first weeks, sometimes after a week or two of feeling tired. No human trial has tested it yet.
Where MOTS-c works.
Appetite & metabolism
In animals. In mice it activates AMPK, the pathway exercise triggers, improving insulin sensitivity and exercise capacity.
Muscle
In animals. Commonly reported in weeks 2 to 4: workouts feel a little easier and endurance pushes further.
Energy & longevity
In animals. A peptide encoded by your mitochondrial DNA, the energy-producing organelles inside every cell.
An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.
Week by week.
What to expect in the first 8 weeks
- Onset
- 1–2 weeks
- Peak effect
- 4–8 weeks
- Duration
- 4–8 weeks
Day 1–14Animal
The first two weeks
Commonly reported in the first two weeks: steadier energy for some, tiredness or feeling flat for others while the body adjusts. MOTS-c switches on AMPK, the metabolic pathway exercise uses, shown so far in mice.
The science
Mechanism: MOTS-c activates AMPK → GLUT4 translocation → increased glucose uptake in skeletal muscle, plus upregulated fatty acid oxidation. In a way, it's an "exercise mimetic" — your cells are getting the same metabolic signal they'd get from a workout, at the mitochondrial level.
Sources- Lee et al. (2015)
Updated Sep 2026
Day 14–28Animal
Workouts often feel easier
Commonly reported in weeks 2 to 4: workouts feel a little easier and endurance pushes further. In mice, MOTS-c raised running capacity at every age tested.
The science
Reynolds 2021 showed MOTS-c improved physical capacity in young, middle-aged and old mice, and that exercise raises MOTS-c in human muscle almost 12-fold; exogenous MOTS-c plus exercise may amplify the signal, which is untested. A single dose raised running time 12% in untrained mice (Hyatt 2022), and a 2025 study found MOTS-c restored mitochondrial respiration in the hearts of rats with type 2 diabetes (Pham 2025).
Sources- Reynolds et al. (2021)
- Hyatt et al. (2022)
- Pham et al. (2025)
Updated Sep 2026
Day 28–56Animal
Weeks 4 to 8: check your markers
If you track fasting glucose or wear a CGM, this is a sensible window to look for movement; the insulin-sensitivity gains so far come from mice. Commonly reported: steadier energy, and for some modest body-composition changes.
The science
A 2024 meta-analysis of 7 observational studies found blood MOTS-c lower in type 2 diabetes but higher in obesity (Zhou 2024), so it isn't a simple marker of metabolic health; whether people with low MOTS-c respond more to injections is untested. A 2025 Experimental & Molecular Medicine paper showed MOTS-c prevented islet senescence in aged mice (Kong 2025).
Sources- Zhou et al. (2024)
- Kong et al. (2025)
Updated Sep 2026
Day 56–84Animal
Diminishing returns + cycle point
Community protocols commonly run 6–12 weeks, but the window is convention rather than evidence — no human interventional data defines an endpoint. If metabolic markers moved, a break here lets you measure what holds; if nothing's shifted, running longer probably won't change that.
The science
A 2023 review notes that no effective way to use MOTS-c in the clinic has been developed (Zheng 2023). No interventional human trial has published as of September 2026: the rodent mechanism work is solid, but human dosing is extrapolated from it.
Sources- Zheng et al. (2023)
Updated Sep 2026
Any dayAnimal
What MOTS-c is built on
MOTS-c is genuinely novel: encoded in your mitochondrial DNA, not your nuclear DNA. The rodent work across metabolic disease, exercise capacity and aging is strong; in people there are only observational studies of natural blood levels, and no trial of the peptide itself.
The science
Discovered in 2015 by Dr. Changhan Lee at USC. A 2024 meta-analysis of 7 observational studies found lower MOTS-c levels in type 2 diabetes (Zhou 2024). Rodent work is rich (AMPK, PGC-1α, islet senescence protection; Kong 2025). Interventional human data is the missing piece, and FDA (April 2026) says it has found no human exposure data.
Sources- Lee et al. (2015)
- Zhou et al. (2024)
- Kong et al. (2025)
Updated Sep 2026
With Retatrutide, Tirzepatide and SemaglutideCommunity
Why MOTS-c pairs with GLP-1s
Two different axes of metabolic health: GLP-1 drugs work on appetite and insulin from the brain-gut side, while MOTS-c works at the mitochondrial level. Commonly reported: steadier energy through a GLP-1 deficit.
The science
No interaction or combination data exist for these pairs. Mechanistically: GLP-1 drives satiety and the pancreatic insulin response; MOTS-c drives AMPK, mitochondrial biogenesis and muscle glucose uptake in mice. The mechanisms barely overlap, which is the rationale for stacking; it hasn't been tested.
Sources- Lee et al. (2015)
- Reynolds et al. (2021)
Updated Apr 2026
Day 1 is the day you start it.
Mouse and cell studies; human data are observational only, with no trials. Effects may be subtle.
Preliminary research
A typical run.
Run notes
- Cycle
- 4–8 week cycles common, 2–3× per year. Common splits: Mon/Thu (2× weekly) or Mon/Wed/Fri (3× weekly). Limited long-term human data — none on continuous dosing.Community practice — opinions vary. Not a clinical recommendation.
- Timing
- Morning injection, pre-exercise or with breakfast for metabolic effect.
- Routes
- SubQ injection, IM injection
- Stacks
- Humanin, SS-31, Ipamorelin
Safety.
Common side effects
- Injection site reaction
- Mild fatigue first week
Interactions
No published human interaction studies exist. Because MOTS-c affects glucose and insulin sensitivity, a mechanism-based consideration applies when combined with insulin or other antidiabetic agents, and glucose monitoring is worth discussing with a clinician. It is frequently stacked with GLP-1 agonists for metabolic goals — no combination-specific human data exists. No documented interaction with SSRIs, anticoagulants, or thyroid meds.
Safety notes
MOTS-c is a mitochondrial-derived peptide regulating glucose and metabolic homeostasis; animal toxicology has been favorable at studied doses, but it has not been established as safe in humans: FDA (April 2026) says it has found no human exposure data for MOTS-c by any route and flags a possible risk of immune reactions to compounded versions. Community-reported effects include transient fatigue (often in the first 1-3 weeks), mild injection-site reactions, and occasional GI upset or palpitations. Because it influences glucose metabolism, glucose-relevant monitoring is a reasonable topic for your clinician. Long-term human safety is unknown.
Goes with.
In the Longevity Core stack
Mitochondrial health & cellular-aging stack
In the Metabolic Reset stack
Triple-agonist appetite control + mitochondrial metabolic optimization
With Retatrutide
Compared with.
Questions people ask.
What is MOTS-c?
A peptide encoded by your mitochondrial DNA, the energy-producing organelles inside every cell. In mice it activates AMPK, the pathway exercise triggers, improving insulin sensitivity and exercise capacity, which is why it's called an "exercise mimetic".
How is MOTS-c dosed in research?
The research range for MOTS-c is 5–10 mg, 2–3× weekly. Studied in research — not a recommendation.
How long does MOTS-c last?
The half-life of MOTS-c is hours (short).
What do people report on MOTS-c?
Commonly reported on MOTS-c: more energy and better workout endurance over the first weeks, sometimes after a week or two of feeling tired. No human trial has tested it yet.
Is MOTS-c safe?
The research basis for MOTS-c is emerging: primarily preclinical / limited human data. Common side effects in the library: injection site reaction and mild fatigue first week.
What does MOTS-c stack with?
Common stacks for MOTS-c: Humanin, SS-31 and Ipamorelin. Curated stacks with MOTS-c: Longevity Core and Metabolic Reset.
Reference.
- Cadence
2–3× weekly
- Half-life
Hours
Hours (short)
- Research basis
●
●●EmergingPrimarily preclinical / limited human data
PepVault for iPhone
Track MOTS-c in PepVault
Log every dose, with reminders on your schedule. 7 days free on the yearly plan for new subscribers.
Open the calculatorHow the vial count worksExplore the live demo
Reviewed How we check the library